1

Audrey’s Life Science Meeting Picks for Jan. 31, 2016 – August 2016

Complimentary Service of AudreysNetwork.com

Jan. 31, 2016

*************************************************************************

Bio2Device Group, Tuesday Morning, Feb. 2, 2016

Topic: “Intellectual Property Protection and Strategy for the New Venture”

Date and Time: Tuesday, Feb. 2, 2016, 8:30am

Location: Sunnyvale City Council Chambers, 456 West Olive Ave., Sunnyvale, CA

George Willman, MBA, JD and Nina Borders, JD Partner and Associate, ReedSmith LLP

There is no fee or registration required for morning meetings.

Event Description

Life science ventures view intellectual property rights as competitive advantages and key

assets. What are intellectual property rights, and how do they provide an advantage to the

new venture? What is a patent, a copyright, a trademark? What intellectual property

strategies should a new venture employ? How does the new venture handle intellectual

property upon founding and during growth to build a strong portfolio? Attend this session to

gain a valuable understanding of how these most important legal concepts are applied in the

business context, and how you may avoid many of the common intellectual property pitfalls

that trouble new ventures.

Speaker Bios

George Willman practices in the areas of technology transactions, patents, and intellectual

property counseling. Representative transactions include licensing, development, service,

distribution, manufacturing, electronic commerce, FinTech and corporate partnering

agreements. He counsels on intellectual property issues raised by merger and acquisition

transactions and initial public offerings. George is a registered patent attorney.

Prior to his legal career, George worked as a software and telecommunications engineer for

ROLM, IBM, and Siemens in Silicon Valley and Munich, Germany.

George serves as a mentor at the Lester Center for Entrepreneurship and Innovation at the

University of California, Berkeley. In addition to English, he speaks German and holds a

Certificat de Français Scientifique et Technique.

Nina Borders is an associate in the firm's Intellectual Property Litigation Group, focusing on

patent and trademark prosecution and litigation. Nina has represented clients in a wide

range of patent, trademark, and trade secret matters in food, chemical, pharmaceutical,

biochemical, and mechanical technologies. Nina has significant experience with trademark

registration and counseling. She also has experience with reexamination proceedings before

the Patent Office and oversees domestic and international trademark and patent portfolios

for clients in a variety of industries. Nina is a registered patent attorney, and has a broad

technical background, with nearly 10 years of experience in the food and pharmaceutical

industries prior to beginning her legal career with Reed Smith.

***************************************************************

BMES Industry Networking Group: San Francisco/Bay Area, Tuesday Evening, Feb.

2, 2016

Topic: “The Future of BioMedicine: Where Can Technology Take Us?”

Speaker: Daniel Kraft, MD, Physician-Scientist, Inventor, Entrepreneur, Innovator

2

Date and Time: February 2, 2016

Schedule:

● 6:00pm Registration, Light Dinner & Networking

● 6:30pm Brief Charter Meeting

● 7:00pm Dr. Kraft’s Presentation

Location: WSGR, 650 Page Mill Rd, Palo Alto, CA

Reduced Introductory Rate:

● $10.00 Advanced registration (by Jan. 30, 2016)

● $15.00 At door, if space available

(cash or check payment only)

Reserve your spot today. Space is limited.

http://bmes.org/sfbayarea

Event Description

What is BMES? The Biomedical Engineering Society (BMES) is the professional society for

biomedical engineering and bioengineering. Founded in early 1968, the Society now boasts

nearly 6,500 members and is growing, rapidly.

Our Group's Mission is as follows: To create a biomedical industry community in the San Francisco Bay Area that provides: * Mentoring for young professionals and newcomers to industry, * Networking, * Continuing Education (e.g., technology, clinical, professional development, industry

trends, funding, regulatory, communication, interviewing), * Promotion of the Industry in the region.

More Information: For more information about joining our Industry Networking Group,

contact Denise Forkey, Cofounder and President, (650) 799-9258 or

denise_forkey@yahoo.com.

Speaker Bio

Daniel Kraft is a Stanford and Harvard trained physician-scientist, inventor, entrepreneur,

and innovator. With over 20 years of experience in clinical practice, biomedical research and

healthcare innovation, Kraft has chaired the Medicine Track for Singularity University since

SU’s inception, and founded and is Executive Director of Exponential Medicine, a program

that explores convergent, rapidly developing technologies and their potential in biomedicine

and healthcare. Following undergraduate degrees from Brown University and medical school

at Stanford, Daniel was board certified in both Internal Medicine & Pediatrics after

completing a Harvard residency at the Massachusetts General Hospital & Boston Children's

Hospital, and fellowships in hematology, oncology and bone marrow transplantation at

Stanford. He has multiple patents on medical device, immunology and stem cell related

research through faculty positions with Stanford University School of Medicine and as clinical

faculty for the pediatric bone marrow transplantation service at University of California, San

Francisco.

*********************************************************************

QB3, Tuesday, Feb. 2, 2016

Topic: “The Series A Preferred Stock Financing: Practical Tips And Strategies For Success”

Speaker: ELTON SATUSKY, Partner, Wilson Sonsini Goodrich Rosati

Date and Time: Tuesday, February 2, noon to 1:00 pm

Location: QB3@953, 953 Indiana St., San Francisco

Onsite parking can be tight. See below for options

Fee: General Admission - $10

3

Register at http://www.eventbrite.com/e/qed-elton-satusky-wilson-sonsini-the-series-a-

preferred-stock-financing-practical-tips-and-tickets-

20442144003?mc_cid=301fb4b035&mc_eid=cb4c38a44a

Speaker Bio

Elton is a partner in the Palo Alto office of Wilson Sonsini Goodrich & Rosati, with a focus on

advising life science companies. He is a trusted advisor and outside general counsel to

founders, management teams and boards of directors on company formations, financing

and strategic transactions, cross-border deals, and corporate governance throughout a

company’s lifecycle. His expertise includes venture financings, mergers and acquisitions,

strategic corporate relationships, and public offerings. He also represents incubators and

accelerators working with start-ups and venture capital in their formation, securities

offerings and investments.

*******************************************************************

QB3, Thursday Midday, Feb. 4, 2016

Topic:”Score! How Your Sbir/Sttr Application Is Reviewed And Scored”

Speaker: David Spellmeyer, Ph.D. Principal at Interlaken Associates

Date and Time: Thursday, Feb. 4, noon to 1:00 pm

Location: Byers Hall, Room 212, UCSF Mission Bay

General Admission: $10

Details and registration at http://www.eventbrite.com/e/qed-david-spellmeyer-score-how-

your-sbirsttr-application-is-reviewed-and-scored-tickets-

20900940275?mc_eid=cb4c38a44a&mc_cid=676b2a966b

Topic Description

The SBIR/STTR grant review process can be extremely frustrating and opaque. But if you

understand how the reviewers operate, you can improve the chances that your application

will succeed. On February 4, David Spellmeyer, an expert SBIR consultant, will reveal the

inner workings of an SBIR/STTR Study Section Review Panel. David’s talk will cover panel

composition, review assignments, meeting mechanics, critiques, and the scoring process.

Join us to learn several ways that you can make your application stand out.

Speaker Bio

David Spellmeyer, Ph.D., is Principal at Interlaken Associates, a consulting firm working with

early stage companies on a wide variety of projects, including SBIR/STTR support. David is

a regular member of SBIR/STTR Study Sections and recently served as Chair of the IMST-

14 Study Section - Small Business: Computational, Modeling, and Biodata Management.

David brings his clients broad technical and business expertise gained in companies both

small and large. He has been involved in the development of several technologies as a

scientist, including combinatorial chemistry, label free screening, and translational

applications of single-cell functional pathway analysis. Development of these technologies

required overcoming many difficult steps of standardization, qualification, and validation of

components of laboratory and information systems for use in clinical applications.

David works very closely with business development teams and has been involved in

establishing over 20 non-dilutive strategic corporate partnerships, 4 mergers and

acquisitions, several rounds of venture financing, one joint venture. He is an Adjunct

Associate Professor at UCSF and an active mentor at UCSF’s Entrepreneurship Center,

California Life Sciences Institute’s FAST Program, and OneStart Americas.

4

*************************************************************************

Medtech Frontiers, Thursday Evening, Feb. 4, 2016D\

Topic:”Driving Healthy Habits through Behavioral Product Design” Date and Time: Thursday, Feb. 4, 2016, 8:00 – 9:00 pm

Location: Triple Ring Technologies, 39655 Eureka Dr., Newark, CA

Cost: The seminar is free, but registration is required for planning purposes. There may be

a small number of walk-in spots available.

Registration and details at

http://events.r20.constantcontact.com/register/event?oeidk=a07ec69jh906cf34b9a&llr=vq

mzncqab

Topic Description

Recent developments in the fields of neurobiology, behavioral psychology, and the science

of decision-making have shone new light on how and why we behave the way we do.

Product designers in healthcare and elsewhere can now leverage these "behavior design"

strategies to create more compelling products and services. If designed appropriately, these

can lead to long-term behavior change in their target audience, extended communities, and

even society at large. Drawing on the seminar work of B.J. Fogg, Nir Eyal, Stephen Wendel

and others, Dr. Sunil Maulik will provide a survey of behavior design and habit formation, as

well as practical strategies for designing products that "diffuse" and "scale" into larger

communities. Expanding on his thesis work on iterative refinement and model-building of

molecular structures, Sunil will show how small, actionable changes and immediate

feedback, when repeated numerous times, can lead to significant changes in the large-scale

behavior of individuals and groups.

Speaker Bio

Sunil's thesis research on mathematical methods for 3-D image reconstruction of self-

assembling biological macromolecular assemblies was published on the cover of the

scientific journal Nature. His book "Molecular Biotechnology" (J. Wiley & Sons) sold over

4000 copies and was used in four university courses. He holds patents in fields as diverse as

gene sequence pattern-matching, e-learning and e-mail analytics. Sunil worked with the

Nobel-prize winners Maurice Wilkins and Aaron Klug as an undergraduate, and Sir Tom

Blundell and Donald Caspar as a graduate student. He has degrees in Physics, Biology, X-

ray Crystallography and Biophysics. Sunil's research on antibody engineering helped

contribute to two therapeutic monoclonal antibodies receiving clinical approval. He has been

a recipient (along with John Teeter and Gene Wang) of a $1.45MM ARPA-E SBIR; and with

Banny Banerjee of the Stanford d-school, a GE "Ecomagination" award.

Sunil participates in several non-profit ventures dedicated to health and wellness in

sustainable communities, including the Pacific AIDS Education Center and Project Ahimsa.

He is enthralled by the opportunity to help extend wellness across the globe by bringing the

power of informatics to everyday users.

***************************************************************

Seminars at Stanford, Tuesday, Mid Day, Feb. 9, 2016

Topic: “Novel Technologies to Investigate the Stem Cell Niche”

Date and Time: Tuesday Feb. 9, 2016, 12:00 pm

Location: Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

Event Details:

5

Small Lunch Served At 12:00��; Lectures Begin At12:15��

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

February 9, 2016

Pre-Seminar Speaker: Michael Lin, Departments of Pediatrics and Bioengineering

February 11, 2016

Seminar Speaker: David Schaffer, UC Berkeley

Novel Technologies to Investigate the Stem Cell Niche

**********************************************************************

Bio2Device Group, Tuesday Evening, Feb. 9, 2016

Topic: “Smarticles: A New Class of Molecular Diagnostic”

Speaker: Diego Rey, PhD , Co-Founder & Head of Research, GeneWEAVE

Date and Time: Tuesday, Feb. 9, 2016, 6:00 pm

Location: Wilson Sonsini Goodrich & Rosati- 650 Page Mill Road, Palo Alto, CA

Cost:

$6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only

$20 - Late Registration and Non-Members

$25 - Walk-ins

Register at www.bio2DeviceGroup.org

Topic Description

Multi-drug resistant organisms (MDROs) threaten modern medicine’s progress by making

common infections fatal and dramatically increasing the risk of complications for many

medical procedures such as surgery, transplants, and chemotherapy. To solve this problem

a global call has been issued to develop new diagnostics that detect MDROs and measure

antibiotic effectiveness fast enough to make time-critical clinical decisions. GeneWEAVE is

using Smarticles(TM) technology to develop fast, simple, and smart diagnostics to aid

healthcare providers in the fight against drug-resistant bacteria by enabling impactful

surveillance programs, early therapy guidance, and successful antibiotic stewardship. This

talk describes the Smarticles technology and tells the story behind GeneWEAVE.

Speaker Bio

Diego Rey co-founded GeneWEAVE in 2010 during his PhD studies at Cornell University.

GeneWEAVE went on to commercialize a platform technology that enables the development

of in vitro diagnostics for detecting bacteria and their antimicrobial susceptibility without the

need for sample preparation. From 2010-2015 Diego served at GeneWEAVE's Chief

Technology Officer during which time the company raised $25MM in venture capital

investment and grew to 50 employees. In August 2015, Roche acquired GeneWEAVE for up

to $425MM. Diego currently serves as the Head of Research for GeneWEAVE, a division of

Roche Molecular Systems, Inc. where he continues to develop simple to use and cost

effective diagnostics with the goal of reducing infections caused by multi drug resistant

organisms worldwide.

*********************************************************************

sfAWIS, Wednesday Evening, Feb. 10, 2016

Event: “Evening of Networking”

Date and Time: Wednesday, February 10, 2016, 6:00-8:00 pm

Location: Valencia & Kebab Restaurant, 525 Valencia Street, San Francisco, Near 16th

Street Mission BART station.

Cost Free. Register at http://www.eventbrite.com/e/sfawis-networking-social-tickets-

16067355894?ref=ebtnebregn via Eventbrite by Tuesday February 9, 2016.

6

Event Description

Join sfAWIS members for a fun evening of networking!

Networking is a great way to meet new people and strengthen existing relationships, hone

your “elevator pitch,” share advice, learn about career opportunities, hear new perspectives,

and learn more about AWIS.

This event is open to all scientists and non-scientists. You do not need to be an AWIS

member to attend.

Appetizers provided.

************************************************************************

ACRP, Thursday Afternoon, Feb. 11, 2016

Event: Mark Your Calendars for the ACRP Virtual Career Fair

Date and Time: Thursday, February 11, 2016 from 9:00 am – 1:00 pm PT (12:00 pm –

4:00 pm EST )

Details and registration at https://app.brazenconnect.com/events/acrp-career-

fair#!eventLanding;eventCode=acrp-career-fair

The ACRP Virtual Career Fair is an excellent resource for clinical research professionals,

like yourself, to connect with the nation's top employers. Create or Update your Job

Seeker Profile NOW and don't forget to flag your resume as a participant in the Virtual

Career Fair!

How the event works:

Discover potential career opportunities, have your resume reviewed, conduct

interviews via online chat and follow-up with recruiters and employers that

interest you

Scout open positions more confidentially than at an onsite career fair

Connect with top clinical research employers regarding their current and future

hiring needs

Click here to ensure your professional profile is up-to-date

***********************************************************************

JLABS, Thursday MidDay, Feb. 11, 2016

Topic: “Lessons in Herding Cats – Business Development Basics for Life Science

Companies”

Speaker: Lesley Stolz, Ph.D. | Sr. Director, Transactions, Johnson & Johnson Innovation,

California

Date and Time: Thursday, February 11, 2016 from 10:45 AM to 1:00 PM (PST)

Agenda:

10:45 AM | Registration Opens

11:00 AM | Presentation

12:00 PM | Q&A

12:15 PM | Lunch and Networking

1:00 PM | Program Close

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd., 3rd Floor, South

San Francisco, CA

7

Fees:

$35 | General Public

$20 | Student/Academic

$45 | Onsite

Register at http://www.eventbrite.com/e/lessons-in-herding-cats-business-development-

basics-for-life-science-companies-tickets-19858437120

Topic Description

The business development professional's purpose is to optimize optionality and long term

value at each stage of a company's life. As a company grows and gains traction, it's easy to

get enticed and overwhelmed by the numerous opportunities that arise. How do you

determine the direction that will add the most value to your company? How do you avoid

the constant pursuit of "shiny objects?" How do you know when it's the right time for a

strategic partnership?

In this workshop, you'll learn fundamental business development skills to help you

successfully evaluate and manage strategic alliances and other potential growth

opportunities.

Topics will include:

Strategic alliance process management

Concepts in valuation

Importance of IP and IP diligence

Communication and negotiation skills

Basic components of a contract

This workshop is geared towards business development professionals and management

teams of life science startups.

Speaker Bio

Lesley has been working in corporate and business development roles for the last 17 years

for companies that are both technology platform and therapeutics focused. Her most recent

executive positions have been with BioTime, a publicly traded stem cell technology and

therapeutic company, and Sutro Biopharma, a platform technology company working in cell-

free protein synthesis. Prior to Sutro, Lesley served in BD positions for a number of biotech

companies in the U.S. and Europe. Lesley received her Ph.D. in chemistry, and conducted

postdoctoral research at Harvard Medical School's Department of Biochemistry and

Molecular Pharmacology.

*****************************************************************

GGPF, Thursday Evening, Feb. 11, 2016

Topic: “Hemoperfusion with Polymeric Adsorbents in the Treatment of Drug-Resistant

Bloodstream Infections”

Speaker: Bob Ward is president of ExThera Medical

Date and Time: Thursday, Feb 11, 6:00 pm

6 PM social hour

7 PM dinner

8 PM lecture

8

Location: Michael's Restaurant at Shoreline Park, 2960 N. Shoreline Park, Mountain View,

CA 94043

Cost:

Employed/postdoc Student/unemployed/retired

Early Registration $30 $15

Registration $35 $20

Walk-in (not guaranteed) $40 $25

Lecture-only is free.

Deadline for registration:

11:59PM, Wednesday, February 3 for early registration discount.

5PM, Wednesday, February 10 for regular registration.

Registration: http://ggpf.org

Topic Description

ExThera Medical Corporation of Martinez, CA has developed the Seraph® Microbind® Affinity

Blood Filter (Seraph). Seraph is a broad-spectrum biomimetic hemoperfusion device that

removes (drug-resistant) pathogens, toxins and pro-inflammatory cytokines from whole

blood. It is designed to reduce the intensity and duration of bacterial and viral infections in

the prevention and treatment of sepsis, a major cause of death all over the world. Methods

of polymer surface modification and characterization we previously applied in the

development of blood and tissue-contacting medical devices were useful in the creation of

Seraph. Synthetic methods that maximize surface concentration of macromolecular ligands

while avoiding stearic hindrance were needed for the successful creation of a non-porous,

antithrombogenic adsorption media that mimics the binding sites used by pathogens when

they invade the human body. Seraph is currently undergoing clinical trials in Europe.

Preclinical testing of a related device, Seraph 200, was performed by Battelle Columbus

within the DARPA Dialysis-like Therapy (DLT) Program where it demonstrated excellent

safety and efficacy in the removal of methicillin resistant Staph. aureus (MRSA).

Speaker Bio

Bob Ward is president of ExThera Medical in Martinez, and founder of Berkeley-based

Polymer Technology Group (PTG), now DSM Biomedical. Bob is a chemical engineer and

polymer scientist with 44 years of experience in the development and manufacturing of

medical devices, and polymeric biomaterials for critical applications. Novel biomaterials and

components developed and manufactured under his direction have been used in dozens of

devices and prosthetic implants including artificial hearts, vascular grafts, stents,

pacemakers, orthopedic implants and contact lenses. ExThera, his fourth start-up venture,

has developed Seraph, a dialysis-like sorbent hemoperfusion device that safely removes

pathogens and toxins from blood in the treatment of drug-resistant bacteremia and

viremia. European clinical trials are currently underway.

************************************************************** HBA, Thursday Afternoon, Feb. 11, 2016

Topic: “Thriving in the 21st Century: How to Build Connected Networks”

Speakers: Sheila Babnis, Innovator in residence, Future State/President Insights & Impacts

and Ayelet Baron, Futurist, chief instigator, speaker, CreatingIs LLC

Date and Time: Thu, Feb 11, 2016, 4:00 PM - 7:00 PM

Agenda

9

4:00 - 4:15 PM Registration and networking

4:15 - 4:30 PM Welcome/BioMarin and HBA introduction

4:30 - 5:30 PM Program and table top discussion

5:30 - 5:45 PM Closing, evaluation, feedback and adjourn

5:45 - 7:00 PM Post program networking Location: BioMarin Pharmaceutical Inc., 770 Lindaro St, San Rafael, CA, 94901

Member rate:

$30 until February 4, 2016

$40 after February 4, 2016

Nonmember rate:

$45 until February 4, 2016

$55 after February 4, 2016

BioMarin employee rate:

$20 until February 4, 2016

$30 after February 4, 2016

Registration information

Event is open to: HBA members and nonmembers

Online registration deadline: February 5, 2016

Onsite (walk-in) registration: Is allowed

Space is limited to 75 registrants

Understand the essence of what it means to build your network and do real work in the 21st

century.

Register at https://my.hbanet.org/MyHBA/EventDetails.aspx?MeetingID=03F0FF27-E3B3-

E511-990B-0050569C00C5

Event description

Life is all about stories. The stories we tell ourselves and the stories we tell others. As

people, we connect with our communities and in the workplace at a human level where trust

and relationships are key to our ability to get people to not only be interested in our story

but also find ways to co-create with us in a meaningful way. We are built to form

attachments and business is all about relationships and we need to go beyond treating it

like a transaction.

A connected network knows no boundaries as it enables people internally and externally to

connect around purpose and common needs and interests. It surpasses organizational

hierarchies to connect people to each other and to ideas. In the 21st century, leaders

moved from seeing a world of scarcity where they needed to compete to one of abundance

where they can create new markets. Possibilities and opportunities are available to those

who understand that the world is open and that social media is just a bunch of tools that

help us reach people in more direct ways. They understand how to use video, for example,

as a strategic tool to build thriving relationships and ultimately, partnerships anywhere in

the world. These leaders know how to arm their business with the most valuable

technologies to reach their goals. They never lead with technology.

The future of work is already here as we live in an open and connected world where it is

easier to connect and have random collisions with people from around the world. We have

co-working spaces, co-creation, co-living spaces, open source and the growing freelance

economy.

The key to the 21st century is the ability of leaders to create space and bring together the

right people at the right time to focus on their top opportunities. In this session, you will

become increasingly aware of why connected networks and trusted communities are key to

your future success in leading in today’s world.

Learning objectives

1. Why are connected networks and communities key to your success

10

2. The seven steps to building your connected network, internally and externally

3. How to work out loud and build lifelong communities

Special instructions: Please bring a government issued ID for check-in. Please park in the

788 Lincoln Avenue garage. There will be a security officer at the entrance to allow each

non-BioMarin attendee in. Employees have a badge to scan in.

******************************************************************* EMBS, Wednesday Evening, Feb. 17, 2016

Topic: “mHealth Physiologic Monitoring Solutions with Ultra Wideband RF Radar”

Speaker: Steve Stephansen, CEO, LifeWave Biomedical

Date and Time: Wednesday, February 17, 2016, 7:30 PM

Location: Room M-114, Stanford University Medical School

Optional dinner location: Stanford Hospital cafeteria, 6:15 PM (no host, no reservations)

Organization contact: http://www.ewh.ieee.org/r6/scv/embs

Topic Description

LifeWave Biomedical, Inc. is an mHealth company that is developing groundbreaking

mHealth monitoring products that are capable of improving health and improving care in

home, remote and medical care settings. LifeWave is a leader in a new class of wireless and

wearable physiologic sensors using a novel, very safe, low energy RF technology for both

consumer and clinical markets. The technology enables internal organ tissue assessments

and real-time monitoring that is unmatched by any other wearable technology. A key

differentiator of the company is the ability to provide products that bridge health and

wellness monitoring with clinical monitoring, enabling continuums of care across settings

and health states.

Speaker Bio

Steve is the CEO of LifeWave Biomedical and is responsible for its general management and

execution. He is a 30 year veteran of the high tech industry and has a strong record of

achievement in the global commercialization of highly innovative technology products. His

domain experience includes semiconductor solutions for high speed computing and signal

processing, Internet video capture systems, and mobile application software. His functional

experience has spanned marketing, sales, business development, and general management

roles in technology companies.

He was previously CEO of WebV2, Inc. and Agoura Technologies, both venture backed

technology copies. He previously held the position of VP of Marketing & Sales at Information

Storage Devices, a semiconductor company, which he grew from product launch to a public

company. He also served in several senior marketing and sales positions at Advanced Micro

Devices (AMD) early in his career and later as VP of Strategic Marketing.

He holds an MS in Management from the Stanford GSB, an MBA from Santa Clara

University, an MSEE from Rensselaer Polytechnic Institute, and a BSEE from Lehigh

University. While pursing his MS in Management at Stanford, he studied medical device

development in the BioDesign program.

**************************************************************************/ JLABS, Thursday, Feb. 26, 2016

Topic: “Meet with….Sofinnova Ventures”

11

Speaker: Mike PowellSofinnova Ventures Participating Representative

Date and Time: Thursday, Feb. 26, 2016; 10:30 am to 1:00 pm

Agenda:

10:30am | Registration Opens and Networking

11:00am | Presentation and Q&A

11:45am | Networking Lunch

1:00-5:00pm | One-on-one Meetings*

*Companies must have applied for a one-on-one meeting ahead of time and be

approved. The application period ends on January 25th, 2016.

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor,

South San Francisco, California

Fees:

Presentation & Lunch

$25 | General Public

$35 | General Public Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of

one-on-one meeting status. Registration to attend the presentation, Q&A, and lunch

will remain open until February 24th, 2016 (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-

one application period ends on January 25th, 2016. Your application will be reviewed

and you will be notified of acceptance by February 11th, 2016. Acceptance of a one-

on-one meeting is not guaranteed as all applications must be approved.

Register at http://www.eventbrite.com/e/meet-with-sofinnova-ventures-tickets-

18715680103?aff=blast

Topic Description

Are you Sofinnova material? Sofinnova Ventures, a leader in funding for life sciences

companies, is visiting Johnson & Johnson Innovation, JLABS. With $2 billion under

management and a recent $500 million fund, Sofinnova is looking to invest in life

science innovators. Focus areas include clinical drug development and drug

discovery.

Since 1974, Sofinnova has partnered with entrepreneurs to secure initial funding,

build successful management teams, form impactful corporate alliances, win key

customers, and navigate acquisitions and IPOs. Sofinnova applies capital and

expertise to guide start-up companies to successful exits. Recent exits include Labrys

Biologics, Tesaro, and Spark.

Representatives from Sofinnova will be in attendance to give an overview

presentation about the company's key areas of interest and best practices when

seeking startup funds. Following the presentation, don't miss this opportunity to

introduce yourself to Mike Powell, General Partner, during the networking lunch. And

finally, for those companies who apply online and are approved, one-on-one meetings

with Sofinnova will provide a forum to discuss your company.

Speaker Bio

Mike Powell, Ph.D. | General Partner, Sofinnova Ventures

12

Mike joined Sofinnova in 1997, and SVP IX ($510M) is his sixth Sofinnova fund. He

has 32 years of experience, including 15 years of R&D before venture. Mike has been

involved in more than 50 clinical programs, and is the author of 90 publications and

books, including a 1,000-page treatise on vaccine design. He was the initial venture

investor of: Actelion (ATLN), Intermune (ITMN), Orexigen (OREX), Seattle Genetics

(SGEN), Threshold (THLD), and Trius (TSRX) and other public and private companies

such as Intellikine (sold to Millennium-Takeda), Mirna and Labrys Biologics (sold to

Teva). Mike was the first person in the biotech industry to be honored by the

American Association of Pharmaceutical Scientists as an AAPS Fellow. He has also

served on the journal editorial boards of Journal of Pharmaceutical Sciences and the

Journal of Controlled Release. He has been the Board President of the AIDS Vaccine

Advocacy Coalition, as well as advisor to the Institute for One World Health, IAVI,

and the Bill and Melinda Gates Foundation. Mike is also Adjunct Associate Professor in

the Department of Pharmaceutical Chemistry at the University of Kansas, one of the

top US pharmacy schools. Before joining Sofinnova, he was group leader of drug

delivery at Genentech. During his tenure there, he and colleagues spun off VaxGen,

an AIDS vaccine company. Prior to Genentech, he helped start Cytel as the Director

of Product Development. Before this he was Senior Scientist and Project Team Leader

at Syntex Research. Mike received his PhD in Chemistry from the University of

Toronto and carried out postdoctoral studies in bio-organic chemistry at the

University of California as a National Science and Engineering Research Council

Scholar. Mike and his wife Tana live in San Francisco, and they enjoy flying, skiing,

diving and flyfishing.

Connect with Mike: Connect on LinkedIn

*****************************************************************

PBSS, Monday, Feb. 29, 2016

Workshop: Advanced LC/MS Practices

Speakers: Jack Henion, Ph.D. Emeritus Professor of Analytical Toxicology, Cornell University

Date: Monday, February 29, 2016, 8:45-17:00

Location: SF Bay Area: Foster City Crowne Plaza

Registration fee (US$): Regular: $195; For unemployed & students: $30; For major-sponsor

rep (incl lunch): $0; For vendor-show rep: $35; For others, details available upon online

login.

Registration: http://www.PBSS.org

Further Information:

Registration deadline: 2/26/2016 (it will close sooner if the seating cap is reached)

About the Topic

Course Objective:

Learn effective LC/MS techniques for analyzing complex samples and characterizing organic

compounds

Who Should Attend:

Experienced LC/MS researchers and practitioners, or others involved in identifying or

measuring organic compounds in real-world samples including drugs and metabolites within

or for the pharmaceutical industry, and who work with HPLC and MS techniques. Prior HPLC

and/or LC/MS experience and understanding is assumed.

Key Topics You'll Learn About:

Principles and preferred practices for APCI LC/MS

Fundamentals and practices for optimal electrospray ionization

13

Principles of multiple charging in electrospray mass spectra of biomolecules

Strategies for characterizing small molecules contained in biological samples via

electrospray LC/MS and LC/MS/MS.

Sample preparation optimized for LC/MS and LC/MS/MS analyses

Initial strategies for interpreting collision-induced dissociation (CID) mass spectra of

small pharmaceutical molecules.

About the Speakers

Jack Henion is Professor Emeritus of Toxicology at Cornell University in the Analytical

Toxicology.. He is also a co-founder, Chairman, and CSO of Advion BioSciences, Inc.,

located in Ithaca, New York. Prof. Henion’s work in LC/MS relates to the analysis of real-

world samples common to pharmaceutical, environmental, and biochemical problems. The

instructor has published extensively in the areas of conventional capillary GC/MS as well as

LC/MS, SFC/MS, IC/MS, and CE/MS using atmospheric pressure ionization (API)

technologies with quadrupole, ion trap, FTMS, and time-of-flight mass spectrometers.

******************************************************************

RAPS, Friday, March 4, 2016

RAPS San Francisco Chapter – “How to Avoid 483 Observations and Audit Non-

Conformities: Lessons from the Trenches”

Speakers:Eric Anderson, supervisory consumer safety office, Food and Drug

Administration and Bradley Chen, managing director, TUV-USA/Nord Industry

representatives to be announced

Date and Time: Friday, March 4, 2016

7:30–8:30 am Registration Check-in and Networking Breakfast

8:30–12:00 pm AM Presentations and Panel Discussions

12:00–1:00 pm Luncheon

1:00–4:15 pm PM Presentations and Panel Discussions

4:30 pm Closing and Adjourn

Location: Crowne Plaza Foster City, 1221 Chess Drive, Foster City, California 94404

Registration: RAPS and ASQ Members: $175 Nonmembers: $200

Details and registration at

http://www.raps.org/EventDetail.aspx?id=23946&utm_source=Email&utm_medium=I

nformz&utm_campaign=Informz%2DEmails

Event Description

Join your quality and regulatory colleagues from ASQ Northern California Biomedical

and the RAPS San Francisco Bay Area Chapter for a lively and informative workshop

that explores effective methods for avoiding common 483 observations and Notified

Body audit non-conformities.

Food and Drug Administration, Notified Body and industry presenters will take a deep

dive into key areas where device and diagnostic companies often have compliance

struggles. Interactive sessions will highlight GMP systems, with particular focus on

CAPAs, Complaints, Design Control, and Risk Management, and use these as a

framework for discussing what’s not working and best practices for how to get it

right. In a bonus segment, a Notified Body Director will provide insight into an

auditor's focus during the MDSAP process.

This workshop will benefit regulatory, quality and R&D personnel from device and

diagnostic companies.

Local Contacts:

14

Barry Craner, ASQ Biomedical Division

Shaalini Doan, RAPS SF Chapter

Michelle Ragozzino, RAPS SF Chapter

Registration Questions:

Shweta Kaushik, RAPS SF Registration Chair

Wesley Carr, RAPS

********************************************************************

sfAWIS, Wednesday Evening, March 9, 2016

Topic: “"Strategic Transitioning: Methodical Job Hunting in Biotech"

Speaker: Mary Arcana

Date and Time: Wednesday, March 9, 2016, 6:30 pm,: 6 pm,

*****************************************************

Stanford, Thursday Mid Day, March 10, 2016

Topic: “Discerning Rare Disease Biomarkers By Micro- And Nanotechnologies”

Date And Time: Thurday, March 10, 2016, Noon

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

Small Lunch Served At 12:00��; Lectures Begin At12:15��

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

March 8, 2016

Pre-Seminar Speaker: Joe Liao, Department Of Urology

March 10, 2016

Seminar Speaker: Jeff Tza-Huei Wang, Johns Hopkins University

Discerning Rare Disease Biomarkers By Micro- And Nanotechnologies

***************************************************************

GGPF, Friday Evening, March 11, 2016

Topic: Designing Simple Polymers with Protein-like Activity: Advanced materials and new

therapies

Speaker: Gregory N. Tew, Professor in the Polymer Science and Engineering Department at

the University of Massachusetts, Amherst

Date and Time: Friday, March 11

6 PM social hour

7 PM dinner

8 PM lecture

Location: Michael's Restaurant at Shoreline Park, 2960 N. Shoreline Park, Mountain View,

CA 94043

Cost:

Employed/postdoc Student/unemployed/retired

Early Registration $30 $15

Registration $35 $20

Walk-in (not guaranteed) $40 $25

Lecture-only is free.

Deadline for registration:

15

11:59PM, Thursday, March 3 for early registration discount.

5PM, Thursday, March 10 for regular registration

Registration: http://ggpf.org

Topic Description

Our primary research aim is to create new materials using a combination of principles,

many of which are inspired by biology. In addition, the design of simple molecules that

mimic the complex structures and functions of biology is at the heart of our work. In this

presentation, we will illustrate some of these principles including novel networks with high

resilience and new delivery agents inspired by protein transduction domains (PTDs).

Coupling high efficiency click chemistry with telechelic polymer design generates new phase

separated networks that are highly elastic and have bicontinuous morphologies over a very

wide compositional range. PTD designs rely on synthetic approaches that easily allow

doubling the density of guanidine functional groups, which increases the transduction

efficiency of the sequences. Cellular uptake studies on three different cell lines (HEK 293T,

CHO, and Jurkat T cells) confirm that these synthetic analogs are highly efficient novel

protein transduction domain mimics (PTDMs), that are more effective than TAT49-57 and

nonaarginine (R9) and also highlights the usefulness of polymer chemistry at the chemistry-

biology interface.

Speaker Bio

Gregory N. Tew, Professor in the Polymer Science and Engineering Department at the

University of Massachusetts, Amherst, has more than a decade of experience transitioning

bio-inspired design concepts to practice.

He received a B.S. in Chemistry from North Carolina State University in 1995 performing

undergraduate research with Prof. D. A. Shultz and interning at Burroughs-Wellcome

Pharmaceutical. In 2000, he earned his Ph.D. from the University of Illinois-Urbana under

Prof. Samuel Stupp in Materials Science after which he joined the Faculty at the Polymer

Science and Engineering Department at the University of Massachusetts, Amherst. Before

starting there, he spent one year in William DeGrado's laboratory at the University of

Pennsylvania Medical School.

His current research interests include bioinspired and biomimetic macromolecules,

molecular self organization, nano-medicine, and materials-immunology. Greg received

every young investigator award offered by the Federal Government including the

Presidential Early Career Award for Scientists and Engineers (PECASE) which is the highest

honor recognized by Federal Funding Agencies for young faculty and presented by the White

House. He was elected as a member of the Defense Science Study Group, founding

member of the ACS Polymer Chemistry Division Fellows program, and served as board chair

of the ACS Division of Polymer Chemistry. More recently he has elected fellow of the ACS

and AIMBE. He has published over 150 peer-reviewed papers and serves as chair of the

SAB for PCCL, Polymer Competence Center Leoben, Austria. Greg remains interested in

technology transfer activities and mentorship. He was a scientific and original co-founder of

PolyMedix; a clinical-stage biotechnology company which has raised over $150M as well as

founding mentor of Future Faculty Workshop: Diverse Leaders of Tomorrow.

***********************************************************************************************************

NCC AWIS,Saturday, March 12, 2016

NCC AWIS Winter Workshop

16

Speakers: Debbie Rocco and Betina Schonberger, Senior Consultants at Interaction

Associates and Ariana Newcomer – The Voice Coach’s Voice Coach and international best-

selling author

Date and Time: Saturday, March 12, 2016, 8:30 am to 2:00 pm

Location: Genentech, Inc. (35-1A), 1475 Grandview Drive., South San Francisco

Event Description

Can you control a room? Influence others? Do you have a "place at the table"? And if you

do, are you comfortable there? We will unlock the mysteries of Executive Presence through

use of voice and other techniques

Debbie Rocco and Betina Schonberger, Senior Consultants at Interaction Associates, partner

with multi-national corporations, non-profits, and educational institutions to develop and

support women leaders around the world. In this workshop, they will help us learn what it

takes to make a positive impact.

Ariana Newcomer – The Voice Coach’s Voice Coach and international best-selling author.

Ariana will help you unlock the secrets of your voice so you can command a room, increase

your influence and effectiveness, and step into authentic leadership.

More details and ticket ordering information will be sent out soon.

Join a supportive group of women to:

-Explore your Field of Authentic Leadership as the core of your personal power

-Unlock the secrets of your voice to increase your influence and effectiveness

-Utilize wholeheartedness as a source of renewed energy ********************************************************************************************** PBSS Workshop, Monday – Friday, March 14-18, 2016

Workshop: “Clinical Trials Essentials: An Intensive One-Week Course (Register for full week or 4-hr sessions)”

Speakers: Edward Rozhon, Mike Huston, Pete Shabe, Savita Sinha, Clarisa Tate, Narinder Singh, Frances Ann McKenney Date and Time:: Monday, March 14, 2016, 12:30-17:00 Registration fee (US$): (USD$)One-week full course: $1865; Mon AM: Drug Development Process: $250; Mon PM: Science of Clinical Trials Design: $250; Tue AM: Clinical Data Management: $250; Tue PM: Applied Statistics in Clinical Trials; Study Site Perspective: $250; Wed AM: Monitoring Clinical Trials: $250; Wed PM: Medical Devices, An Overview: $250; Thur AM: GCP & ICH Investigator & Clinical Research Site: $250; Thur PM: Clinical QA/Compliance Audits and the FDA: $250; Good Manufacturing Practices and regulatory trends: $250; Fri PM: Global Clinical Trials Perspective; Business of Clinical Research: $250; Location: SF Bay Area: 2505 Augustine Dr, Santa Clara (UCSC-Extension in Silicon Valley) Registration: http://www.PBSS.org Registration deadline:3/12/2016 (it will close sooner if the seating cap is reached)

About the Topic

Clinical Trials Essentials: An Intensive One-Week Course

A joint course between UCSC Extension Silicon Valley and

17

Pharmaceutical & BioScience Society -- San Francisco Bay

March 14-18, 2016

(Register for the full-week or any half-day sessions) Monday March 14, 2016 – 8:30 am—12:30 pm

Drug Development Process 4 hours – Edward Rozhon

Major players in drug development

Assay development and discovery of new medical entities

Non clinical and clinical development of new drugs

History and regulatory oversight of FDA

Structure of Phase I, II, & III clinical trials

FDA review of New Drug Application.

Monday March 14, 2016 – 1:30 pm—5:30 pm

Science of Clinical Trials Design 4 hours – Mike Huston

Phases of drug development

Objectives of clinical studies

Basic clinical trials designs

Underlying science for clinical trials designs.

Tuesday March 15, 2016 – 8:30 am—12:30 pm

Clinical Data Management 4 hours – Speaker TBA

Key data management activities for study startup, conduct, and closeout

Regulations applicable to data management activities

Clinical data management systems and electronic data capture (EDC)

Working with contract research organizations (CROs) for data management.

Tuesday March 15, 2016 – 1:30 pm—3:30 pm

Applied Statistics in Clinical Trials 2 hours – Pete Shabe

The role statistics plays in clinical research

Basic data summarization techniques

Estimation and Hypothesis Testing Introduction

Estimation and Confidence Intervals

Statistical Hypothesis Testing.

Tuesday March 15, 2016 – 3:45—5:30 pm

Study Site Perspective 2 hours – Speaker TBA

Translational research in an academic center: fundamental strengths and

weaknesses

Research Process and Operations management as the success of a trial

Essential conversations between academia, biomedical and pharmaceutical

companies, venture capitalists and consultants

Data Integrity and well-supported metrics (Case Studies).

Wednesday March 16, 2016 – 8:30 am—12:30 pm

Monitoring Clinical Trials 4 hours – Savita O. Sinha

Review the basic regulatory requirements of monitoring a clinical research study

Describe the tasks that should be performed before, during, and after a monitoring

visit

Learn how to track all key parameters involved in monitoring a site

Know how to complete visit reports and follow-up on action items after each site

visit.

Wednesday March 16, 2016 – 1:30 pm—5:30 pm

18

Medical Devices, An Overview 4 hours – Clarisa Tate

What is a medical device, an general overview of regulations

Medical devices regulatory pathways: 510(k), PMA, and HDE

Medical device clinical trials: Focus on Investigational Device Exemptions

Post-market surveillance: Focus on 522, complaints, and recalls

Globalization and changing regulatory environment.

Thursday March 17, 2016 – 8:30 am—12:30 pm

GCP & ICH Investigator & Clinical Research Site 4 hours – Narinder Singh

Historical and legislative roads to Good Clinical Practices (GCP)

Principles of GCP and the research-care conflict

Role of various stakeholders in Clinical Trials

Elements of informed consent.

Thursday March 17, 2016 – 1:30 pm—5:30 pm

Clinical QA/Compliance Audits and the FDA 4 hours – Frances Ann McKenney

Qualifications needed for GXP auditors and FDA Inspectors

Objectives of sponsor audits and regulatory inspections

Similarities and differences between sponsor audits and regulatory inspections

General approach to hosting an audit or inspection

Types of findings that cause concern for auditors or inspectors.

Friday March 18, 2016 – 8:30 am—12:30 pm

Good Manufacturing Practices and regulatory trends 4 hours – Narinder Singh

Good Manufacturing Practices (GMP) for drugs

GMP for biologics and related products, including Good Tissue Practices

Considerations for Quality Systems.

Friday March 18, 2016 – 1:30 pm—2:30 pm

Global Clinical Trials Perspective 1 hour -- Narinder Singh

Trends in global clinical trials.

Role of FDA and local regulatory culture.

Friday March 18, 2016 – 2:45 pm—5:30 pm

Business of Clinical Research 2 hours – Mike Huston

The Market Players – Pharma, Biotech, Contract Research Organizations (CROs)

Cost of Doing Business – Cost of conducting clinical research

Outsourcing and CROs – It costs money to make money

Innovative Ways to Reduce Cost – Business Strategies and Process Innovations.

***********************************************************************************************************

JLABS, Tuesday Morning, March 15, 2016

Event: “Meet with GE”

GE Representative: Alex de Winter | Director, Healthcare Ventures, GE Ventures

Date and Time: Tuesday, March 15, 2016,

10:30am | Registration Opens and Networking

11:00am | Presentation and Q&A

11:45am | Networking Lunch

1:00-5:00pm | One-on-one Meetings*

Location: Johnson & Johnson Innovation, JLABS, 329 Oyster Point Blvd - 3rd Floor, South

San Francisco, California

Fees:

Presentation & Lunch

19

$25 | General Public

$35 | General Public Onsite

Includes presentation, Q&A, and lunch. All attendees must pay this fee, regardless of one-

on-one meeting status. Registration to attend the presentation, Q&A, and lunch will remain

open until March 14th, 2016 (or sold out).

One-on-One Meeting

FREE | Application

FREE | Accepted Companies

Companies must have applied for a one-on-one meeting ahead of time. The one-on-one

application period ends on February 17th, 2016. Your application will be reviewed and you

will be notified of acceptance by March 1st, 2016. Acceptance of a one-on-one meeting is

not guaranteed as all applications must be approved.

Details and Registration:

http://www.eventbrite.com/e/meet-with-ge-ventures-tickets-19183383015?aff=weekly

Topic Description

Accelerate your Innovation with a capital partner that can help scale your ideas and grow

your company! GE Ventures' unrivaled access to a global network of GE expertise and

resources along with investment capital can help bring business to the next level. GE

Ventures' investment themes include:

• Digital Health - Use of combinations of devices, sensors, software, services and data

to improve patient care

• IT/Service - Software and connectivity solutions that improve efficiency and decision

making

• Minimally Invasive Procedures - Devices that enable new less invasive methods to

deliver therapies and diagnostics

• Precision Medicine - Life science tools and diagnostics that enable personalized care

Representatives from GE Ventures will be in attendance to give an overview presentation

about the company's key areas of interest and funding opportunities. Following the

presentation, don't miss this opportunity to introduce yourself to Alex DeWinter, Director,

Healthcare Ventures during the networking lunch. And finally, for those companies who

apply online and are approved, one-on-one meetings with GE Ventures will provide a forum

to discuss your company.

*Companies must have applied for a one-on-one meeting ahead of time and be approved.

The application period ends on February 17th, 2016.

GE Ventures Participating Representative’s Bio

Alex de Winter invests in life science instrumentation and clinical diagnostics startups,

leading GE Ventures' investment in Veracyte (VCYT). Alex joined GE Ventures from Mohr

Davidow Ventures, where he served as a board director with On-Q-ity and board observer

for CardioDx, Corventis, Crescendo Bioscience, didimi, DVS Sciences, and Personalis. He

started his career as a research scientist with 454 Life Sciences (acquired by Roche) and

Pacific Biosciences (PACB). Alex has an MBA from UC Berkeley, a Ph.D. in chemistry from

Stanford, and graduated magna cum laude from Amherst College with a BA in English and

Chemistry. When not working, Alex enjoys cooking and supporting/lamenting the Dallas

Cowboys. *************************************************************************************************************

20

QB3,Thursday, March 24, 2016

Topic: “Advances In Biologics Development And Delivery”

Moderated by: Prof. Carolyn Bertozzi

• Kent Iverson, Biotechnology Consultant and Contractor

• Dr. Douglas Crawford, Assoc. Director, QB3

Dr. Greg Bleck, Global Head R&D, Biologic, Catalent Pharma Solutions

Date and Time: Thursday, March 24, 8:00 to 5:00 pm

AGENDA

8:00-8:30 Registration and Breakfast

8:30-8:45 Welcome and Introduction Dr. Cornell Stamoran Managing Director, Catalent

Institute; Prof. Carolyn Bertozzi Professor of Chemistry, Stanford University

8:45-9:30 Asialoglycoprotein receptor mediated delivery of antisense oligonucleotides to

hepatocytes enhances potency >10-fold in animals Dr. Punit Seth Exec

Director, Med Chem Ionis Pharmaceuticals

9:30-10:15 Monoclonal Antibodies To HLA/Peptide Tumor Antigens Dr. William

Hildebrand Founder/Chief Scientist

Pure MHC

10:15-10:30 Break

10:30-11:15 Antibody Drug Conjugates Using SmarTag Technology Dr. David Rabuka

Global Head R&D, Chem Bio Catalent Pharma Solutions

11:15-12:00 Ultralong CDR3s Of Cow Antibodies: Biology And Engineering Dr. Vaughn

Smider

Chief Scientific Officer, Sevion

12:00-1:30 Networking Lunch & Meet The Experts

1:30-2:15 Construction Of Versatile Carriers For Therapeutic Cargo Using Viral Capsids

Prof. Matt Francis

Professor of Chemistry, UC Berkeley

2:15-3:00 Latest Trends And Development In Non-Invasive Macromolecule Delivery

Dr. Randy Mrsny

CSO & Co-Founder, Applied Molecular Transport

3:00-3:30 Break

3:30-4:30 Expert Panel Discussion: Trends In The Development And Delivery Of

Biologics Moderated by: Prof. Carolyn Bertozzi

• Kent Iverson, Biotechnology Consultant and Contractor

• Dr. Douglas Crawford, Assoc. Director, QB3

• Dr. Greg Bleck, Global Head R&D, Biologic, Catalent Pharma Solutions

4:30-4:45 Closing Remarks

Please join us for a cocktail reception following the session from 5:00 PM – 7:00 PM.

Location: UCSF Mission Bay, Genentech Hall, Byers Auditorium

Register at https://www.eventbrite.com/e/advances-in-biologics-development-and-delivery-

tickets-20142658233?mc_cid=b9047f4535&mc_eid=cb4c38a44a

Event Description

Catalent Institute experts from Catalent Pharma Solutions, Ionis Pharmaceuticals, Pure

MHC, Sevion, UC Berkeley, and Applied Molecular Transport will present on the latest

developments in development of biological therapies and delivery. This event is designed to

cater to VPs, directors, principal investigators and graduate students joining us from leading

pharmaceutical companies and universities.

21

The expert panel, moderated by Professor Carolyn Bertozzi (Stanford University, formerly of

QB3-Berkeley), will focus on providing solutions for biologic development challenges facing

every R&D team today. Participants are encouraged to bring their toughest development

challenges to discuss with the expert panel.

********************************************************************************************************

EPPICON, Saturday, March 26, 2016

Event: EPPICon 2016

March 26, 2016, 8:00pm

Location: Crowne Plaza Hotel San Francisco Airport 1177 Airport Blvd, Burlingame, CA

94010

The Tenth Annual flagship event from EPPIC Global Network, a non-profit professional

organization in the San Francisco Bay Area with a mission to provide a platform for fostering

entrepreneurship, professional networking and mentoring in the life sciences and healthcare space.

Save The Date: Saturday, March 26, 2016

Who Should Attend

Entrepreneurs, Innovators, Researchers, Investors and Professionals (including Service Providers) from Pharma, Biotech, Diagnostics, Devices and Digital Health

Past Speakers at EPPICon

Vivek Wadhwa, Kim Bush, Ann Lee, Corey Goodman, Hal Barron, Norman Winarsky, Kiran Mazumdar-Shaw, Kevin Davies and many more…

Stay tuned - we will be back with more!

Visit us at www.eppicglobal.org

Chitra Sharma (Convenor, EPPICon 2016 & EPPIC President Elect)

Anjali Pandey & Amita Goel (Co-Chairs, EPPICon 2016 & EPPIC Charter Members)

EPPICon 2016 Organizing Committee

EPPIC GLOBAL

www.eppicglobal.org

eppic@eppicglobal.org (408) 357-0601

**************************************************************

JLABS, Tuesday Afternoon, March 29, 2016

Topic: “Choose Your Exit: How to Benefit from IPO Preparation”

Speakers:

Matthew Hudes | US Managing Principal, Biotechnology, Deloitte Consulting LLP,

Angela Rusakova | West Region Life Sciences Audit Partner, Deloitte & Touche LLP

Date and Time: Tuesday, March 29, 2016

Agenda:

12:00 PM | Registration Opens, Lunch and Networking

12:40 PM | Life sciences company - life events

1:10 PM | Financing strategies

22

1:30 PM | Exit strategy: M&A vs. IPO

1:50 PM | IPO requirements - Job Act

2:20 PM | Coffee Break

2:30 PM | Ready for IPO?

3:00 PM | Going through the IPO process

3:30 PM | Company post IPO

3:50 PM | Next events: IPO readiness bootcamp; Lessons learned

4:00 PM | Program Close

Location: JLABS, 329 Oyster Point Blvd - 3rd Floor, San Francisco, CA

Fees:

$30 | General Public

$45 | Onsite

Details and registration at http://www.eventbrite.com/e/choose-your-exit-how-to-

benefit-from-ipo-preparation-tickets-20106147027?aff=weekly

Topic Description

The business development professional's purpose is to optimize optionality and long

term value at each stage of a company's life. As a company grows and gains traction,

it's easy to get enticed and overwhelmed by the numerous opportunities that arise.

How do you determine the direction that will add the most value to your company?

How do you avoid the constant pursuit of "shiny objects?" How do you know when it's

the right time for a strategic partnership?

At this event, you will learn how to prepare your company for IPO as well as the key

differences between M&A and IPO exits. Key focus areas include:

• What are the key decisions you need to make and when do you need to make

them?

• When is the right time to develop your exit strategy?

• Key considerations and differences between M&A and IPO exits

• Job Act requirements

• SEC requirements for IPO and post IPO

• Key stakeholders to manage through the IPO process

• Company’s internal processes pre- and post-IPO

Deloitte will share their experiences working with startup life sciences companies

through the IPO process and beyond. The skills learned during this program are

valuable to all young companies whether or not they eventually go through an IPO.

This "How to... Workshop" is geared towards life sciences startups.

As with all of our events, the "How to... Workshop" is interactive and informal so

bring your questions with you!

Speakers' Bios

Matthew is the BioPharma segment leader for Deloitte’s Life Sciences practice sector.

He speaks frequently about such topics as fostering innovation, personalized

medicine, the use of technology for innovating clinical research, finance

transformation, manufacturing and quality, regulatory compliance, and supply chain.

Matthew is the executive sponsor of Deloitte’s unique innovation collaboration with

the University of California, and is the Lead Client Service Principal for the California

Institute for Quantitative Biosciences (QB3). He is a member of the Board of

Directors of BIOCOM and of the Bay Area BioEconomy Initiative, and a faculty

member and executive sponsor of the UC Berkeley BioExec Institute.

23

Angela has 20 years of experience serving both public and private companies with a

focus on the life sciences industry. She works with companies in all stages of growth,

from start-ups to SEC registrants. Her technical background includes complex

accounting issues such as revenue recognition, equity, derivatives, stock-based

compensation, and acquisitions. Angela has been involved in financing and M&A

transactions, including initial public offerings, offerings in leveraged buyouts, and

several secondary shares offerings. She has extensive international experience and is

a certified public accountant in the United States and the United Kingdom. Angela

also served as a CFO before returning to public accounting in 2003.

********************************************************************

BioX Program Stanford, Thursday Mid Day, April 7, 2016

Topic: “Optical Control and Interrogation of Protein Activity Using Engineered

Photoreceptors”

Speaker: Speaker: Bianxiao Cui, Department of Chemistry

Thursday, April 7, 2016, 12:00 pm

Location:

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360

SMALL LUNCH SERVED AT 12:00��; LECTURES BEGIN AT12:15��

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360

*************************************************************

Bio-X Frontiers, Tuesday, April 26, 2016

Topic: “Integration Of Systems Biology, Tissue Engineering, And Microdevices For Drug

Development”

Pre-Seminar Speaker: Ovijit Chaudhuri, Department Of Mechanical Engineering

April 28, 2016

Seminar Speaker: Linda Griffith, Mit --Integration Of Systems Biology, Tissue Engineering,

And Microdevices For Drug Development

Date And Time: Tuesday, April 26, 2016, Noon

Location:

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

Small Lunch Served At 12:00��; Lectures Begin At12:15��

Pre-Seminars In Clark Center Room S361; Seminars In Clark Center Room S360

********************************************************

Bio-X, Saturday, May 7, 2016

In vitro Vascularized Constructs as Models of Metastatic Cancer

Date and Time: Saturday, May 7, 2016, noon

Location:

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360

SMALL LUNCH SERVED AT 12:00��; LECTURES BEGIN AT12:15��

PRE-SEMINARS IN CLARK CENTER ROOM S361; SEMINARS IN CLARK CENTER ROOM S360

24

Pre-Seminar Speaker: Alexander Dunn, Department of Chemical Engineering

May 19, 2016

Seminar Speaker: Roger Kamm, MIT In vitro Vascularized Constructs as Models of Metastatic Cancer

***************************** sfAWIS, Wednesday Evening, May 11, 2016

Topic: "The Conflict Shift: from Conflict to Cooperation"

Speaker: Susan Berstein, MBA, PhD

Date and Time: Wednesday, May 11, 2016, 6:30 pm,:

******************************************************************* BIO International Conference, June 6 – 9, 2016

Dates: June 6 – 9, 2016

Location: Moscone Convention Center, North, South and West Halls

Fees: Convention Access - $1,200, Members and 1,450, Non Members before April 16;

$1,400, Members and $1,750 for nonmembers after April 16 (see other package pricing at

http://convention.bio.org/register/)

*****************************************************************

BIO Career Fair, Thursday Afternoon, June 9, 2016

Event: BIO Career Fair

Date and Time: Thursday, June 9, 2016, 2:00 – 7:00 pm

Cost: Free

Details and registration at http://convention.bio.org/careerfair-jobseekers/

BIO is proud to announce the 2016 BIO Career Fair, Thursday June 9 from 2:00 - 7:00 pm.

As an extension of BIO’s online job board—Bio Jobs—the Career Fair will provide an

opportunity for meeting participants and top employers to discuss career opportunities..

The BIO Career Fair (is free) and will allow you access to many of the world’s leading life

science companies. A minimum of a 4-year life science degree OR a community college

biotech degree is recommended and military veterans are encouraged to apply. Details at More information coming soon!

*********************************************************************

HPLC, Sunday, June 19, 2016

Topic: “HPLC 2016 - 44th International Symposium and Exhibit on High Performance Liquid

Phase Separations and Related Techniques”

Date and Time: Sunday, June 19, 2016 , 8:30 am

Location: Mariott San Francisco Marquis

The goal of HPLC 2016 is to bring together scientists who use and develop

HPLC, capillary electrophoresis, supercritical fluidic chromatography, microfluidics, and mass

spectrometry to exchange ideas, best practices, and

latest developments. The conference program is guided by emerging trends in

separations technology and their impact on science and society.

THREE SESSION TRACKS AT HPLC 2016:

25

Technology: Better, Faster, Quantitative Separations

Interface to MS: Improving Information Content

BioAnalysis and Applications: Impacting Science and Society

Topics include column and stationary phase technology, interface to mass spectrometry,

microfluidic systems, capillary electrophoresis, LCxLC, QA&QC methods, QbD in separations,

and application to real world problems. A special emphasis in applications will be on

bioanalysis including:

pharmaceuticals, antibody-drug conjugates, antibody characterization, biotechnology,

proteins and proteomics, glycomics, metabolomics and lipidomics, food and nutrition, well-

characterized biologicals, biofuels, environment, and toxicology.

Also Featuring:

Tutorials, Short Courses, User Group Meetings, and Lunch Technical Sessions

For more information, visit: www.hplc2016.org

http://www.hplc2016.org/index.html

Type of Registration: Fees are posted under the "Online Registration" tab located at

www.HPLC2016.org.

Payment must be made by check or credit card payable in US Dollars and drawn on a US bank (no bank wire transfers).

Registration is not accepted or acknowledged until payment is received.

By submitting this registration, you authorize the HPLC 2016 meeting to share your information with attendees, etc.

Student Registrants: In order for the student rate to be accepted, must submit proof of

current full-time graduate or undergraduate, not postdoctoral, status at an academic

institution by providing both a copy of your Student I.D and a letter on university stationery

from your department chair along with the department chair contact details and email. Email the letter and copy of the Student ID to janet@barrconferences.com.

All Oral and Poster Presenters: In order to present, the presenting author of each lecture

and poster must be registered as a conference attendee (not booth staff) and must

complete the registration process by paying online by April 18 to confirm intent to attend

and present at the meeting. If fees are not paid, submissions from that author will be removed from the program.

Refund Policy: A processing fee of 20% will be collected on cancellations on or before April

1, 2016, after which the fees are non-refundable. Registration is transferable; must contact

Symposium Manager by no later than one week prior to the conference to transfer and

receive confirmation of the transfer of the registration (janet@barrconferences.com or telephone 301-668-6001).

HPLC 2016 Symposium/Exhibit Manager

Ms. Janet Cunningham

Barr Enterprises

www.LinkedIn.com/in/BarrEnterprises

phone 301-668-6001

janet@barrconferences.com www.HPLC2016.org

26

***********************************************************

Bio2Device Group, Tuesday Evening, August 9, 2016

Topic: TBA

Speaker: Dr. Allison Dupuy, Partner, Simon-Kucher

Date and Time: Tuesday, Aug. 9, 2016, 6:00 pm

Date and Time: Tuesday, Oct. 13, 2015, 6:00pm

Location: Wilson Sonsini Goodrich & Rosati, 650 Page Mill Road, Palo Alto CA

Cost:

$6 - Students/In-transition - Members only

$11 - Early-bird Registration - Members only

$20 - Late Registration and Non-Members

$25 - Walk-ins (as space permits)

Register at www.Bio2DeviceGroup.org

Speaker Bio

Dr. Allison Dupuy is a Partner in the Life Sciences division of Simon-Kucher & Partners in

San Francisco and leads the company’s life sciences practice on the west coast of the

US. She joined the team in San Francisco in August 2012 after spending 5 years in

Simon-Kucher’s Boston office.

In her work at Simon-Kucher, she focuses on strategic pharmaceutical marketing, value-

to-customer, market entry strategies, pricing and market access strategies, innovative

pricing strategies, product lifecycle strategies, licensing and valuation, market

forecasting and value communication, including global value story development and

implementation. She is a trusted advisor of leading pharmaceutical and biotech

companies across a wide range of therapeutic areas in all major healthcare markets

across the globe.

Dr. Dupuy received her Ph.D. and M.Phil. in Molecular Biophysics and Biochemistry from

Yale University and a B.A. in Physics with honors from Wellesley College where she was

a Goldwater Scholar and a Schiff Fellow.

She is the author and coauthor of several scientific publications and has research

experience in theoretical and experimental physics, biophysics, cell biology, cancer

biology, genomics, proteomics, bioinformatics and biochemistry.